{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:18Z","timestamp":1793157438237,"version":"4.5.0"},"reference-count":19,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1UM1TR004906"],"award-info":[{"award-number":["1UM1TR004906"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Concurrent use of medications can modulate the effectiveness of immunotherapy. Although this interaction is well documented for immune checkpoint inhibitors, whether this occurs with new experimental compounds has not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A computerized data extraction tool was used to collect clinical data and identify the prescription of a predefined set of medications within 30 days of immunotherapy infusion in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. The primary endpoints were median overall survival (OS) and progression-free survival. Tumor responses were assessed using RECIST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 897 patients. The most prevalent tumor types were colorectal (24.5%), head and neck (10.5%), and pancreatic (9.4%). The immunotherapy administered consisted of monoclonal antibodies and fusion proteins (64.7%), immune modulators (IM; 20.8%), combinations of IMs and antibodies (9.2%), and oncolytic viruses and cancer vaccines (5.3%). The most frequently prescribed drugs were narcotics (70.5%), antiemetics (49.1%), antihistamines (34.6%), antibiotics (31.2%), and proton pump inhibitors (PPI; 28.7%). Patients receiving antihistamines exhibited increased rates of stable disease and partial response (\u03c72 8.48; P = 0.014) on the IMs and antibodies combination. The benefit of antihistamines was confirmed in a multivariate analysis of OS [HR, 0.752 (95% CI, 0.603\u20130.938); P = 0.012]. For patients with colorectal cancer, PPI use was associated with shortened survival, with a median OS of 5.2 months with PPI use and 8.6 months without it (P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings highlight the need for strategies to guide concurrent medication choices for patients receiving immunotherapy in early-phase trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Concurrent administration of antihistamines correlates with enhanced survival in patients receiving experimental immunotherapy for cancer. Conversely, PPI use diminishes survival in patients with colorectal cancer. These findings highlight how tumor immunogenicity and drug interactions can modulate response and survival outcomes, offering new insights to optimize investigational immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0033","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:32:45Z","timestamp":1756297965000},"page":"1631-1641","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-8011","authenticated-orcid":false,"given":"Camila","family":"Braganca Xavier","sequence":"first","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-9117","authenticated-orcid":false,"given":"Clark R.","family":"Andersen","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3264","authenticated-orcid":false,"given":"JoAnn","family":"Lim","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-6296","authenticated-orcid":false,"given":"Julian H.","family":"Slade","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-2945","authenticated-orcid":false,"given":"Stacie A.","family":"Bean","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-7261","authenticated-orcid":false,"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8886-926X","authenticated-orcid":false,"given":"Hung","family":"Le","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-0536","authenticated-orcid":false,"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"Jordi","family":"Rodon Ahnert","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7914-5162","authenticated-orcid":false,"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":false,"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-9518","authenticated-orcid":false,"given":"Tin-Yun","family":"Tang","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-0419","authenticated-orcid":false,"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2025091505344740100_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025091505344740100_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025091505344740100_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.annonc.2022.05.010","article-title":"Impact of acetaminophen on the efficacy of immunotherapy in cancer patients","volume":"33","author":"Bessede","year":"2022","journal-title":"Ann Oncol"},{"key":"2025091505344740100_bib4","doi-asserted-by":"crossref","first-page":"e2322922","DOI":"10.1001\/jamanetworkopen.2023.22922","article-title":"Is immunotherapy with concomitant proton pump inhibitor use a viable combination?","volume":"6","author":"Stefani","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025091505344740100_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"2025091505344740100_bib6","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-20-3855","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research washout period and concomitant medication work group","volume":"27","author":"Harvey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025091505344740100_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025091505344740100_bib8","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","article-title":"Obesity induces PD-1 on macrophages to suppress anti-tumour immunity","volume":"630","author":"Bader","year":"2024","journal-title":"Nature"},{"key":"2025091505344740100_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"key":"2025091505344740100_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2025.02.010","article-title":"Efficacy assessment in phase I clinical trials: endpoints and challenges","volume":"36","author":"Gouda","year":"2025","journal-title":"Ann Oncol"},{"key":"2025091505344740100_bib11","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2025091505344740100_bib12","doi-asserted-by":"crossref","first-page":"1070076","DOI":"10.3389\/fimmu.2023.1070076","article-title":"Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis","volume":"14","author":"Lopes","year":"2023","journal-title":"Front Immunol"},{"key":"2025091505344740100_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"key":"2025091505344740100_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"2025091505344740100_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2025091505344740100_bib16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut microbiota in cancer immune response and immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"2025091505344740100_bib17","doi-asserted-by":"crossref","first-page":"e2322915","DOI":"10.1001\/jamanetworkopen.2023.22915","article-title":"Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with Non\u2212Small cell lung cancer","volume":"6","author":"Kawachi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025091505344740100_bib18","doi-asserted-by":"crossref","first-page":"1805007","DOI":"10.1002\/adma.201805007","article-title":"Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis","volume":"30","author":"Song","year":"2018","journal-title":"Adv Mater"},{"key":"2025091505344740100_bib19","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.3390\/curroncol30090589","article-title":"Effects of acetaminophen exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small-cell lung cancer: a propensity score-matched analysis","volume":"30","author":"Nelli","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0033\/3646404\/crc-25-0033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1631\/3650967\/crc-25-0033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1631\/3650967\/crc-25-0033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:34:54Z","timestamp":1757928894000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1631\/765135\/Modulating-Treatment-Outcomes-of-Patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0033","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30126789","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126786","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126792","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30126780","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8034957","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}